Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism

• Published in: Clinical endocrinology (Oxford) Vol. 96; no. 2; pp. 200 - 219
• Main Authors: Jayasena, Channa N., Anderson, Richard A., Llahana, Sofia, Barth, Julian H., MacKenzie, Finlay, Wilkes, Scott, Smith, Neil, Sooriakumaran, Prasanna, Minhas, Sukhbinder, Wu, Frederick C. W., Tomlinson, Jeremy, Quinton, Richard
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01-02-2022
• Subjects: diagnosis treatment and monitoring; Endocrine System Diseases; Endocrinology; guidance, male hypogonadism; Hormone Replacement Therapy; Humans; Hypogonadism; Hypogonadism - drug therapy; Male; Medical diagnosis; Patients; Primary care; sexual dysfunction; testis, testosterone; Testosterone; Testosterone - therapeutic use; testis, testosterone; sexual dysfunction; diagnosis treatment and monitoring; guidance, male hypogonadism
• ISSN: 0300-0664; 1365-2265
• DOI: 10.1111/cen.14633

Male hypogonadism (MH) is a common endocrine disorder. However, uncertainties and variations in its diagnosis and management exist. There are several current guidelines on testosterone replacement therapy that have been driven predominantly by single disciplines. The Society for Endocrinology commissioned this new guideline to provide all care providers with a multidisciplinary approach to treating patients with MH. This guideline has been compiled using expertise from endocrine (medical and nursing), primary care, clinical biochemistry, urology and reproductive medicine practices. These guidelines also provide a patient perspective to help clinicians best manage MH.